Belite Bio, Inc BLTE

BLTE Company Overview

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for retinal degenerative diseases that currently lack effective treatment options. The company operates within the biotechnology and ophthalmology industries, with a primary emphasis on inherited and age-related retinal disorders. Belite Bio’s core strategy centers on targeting the visual cycle to slow or prevent toxic byproduct accumulation associated with retinal degeneration.

The company’s lead product candidate is LBS-008 (tinlarebant), an orally administered small-molecule designed to reduce the formation of vitamin A–derived toxins in the retina. This candidate represents the company’s principal revenue driver potential and is being developed primarily for Stargardt disease and dry age-related macular degeneration (dry AMD). Belite Bio was founded in 2017 and has since evolved from early research activities into a late-stage clinical development company, culminating in its public listing in the United States.